|
Index | - | P/E | - | EPS (ttm) | -0.96 | Insider Own | - | Shs Outstand | 28.46M | Perf Week | 6.53% |
Market Cap | 1.11B | Forward P/E | - | EPS next Y | -1.70 | Insider Trans | - | Shs Float | 21.19M | Perf Month | 38.07% |
Income | -56.40M | PEG | - | EPS next Q | -0.44 | Inst Own | 95.70% | Short Float | 3.10% | Perf Quarter | 23.89% |
Sales | - | P/S | - | EPS this Y | -107.10% | Inst Trans | 4.56% | Short Ratio | 4.29 | Perf Half Y | 17.51% |
Book/sh | 12.84 | P/B | 2.42 | EPS next Y | 54.90% | ROA | -37.80% | Target Price | 35.33 | Perf Year | - |
Cash/sh | 10.38 | P/C | 2.99 | EPS next 5Y | 38.60% | ROE | -649.20% | 52W Range | 15.33 - 38.01 | Perf YTD | 23.89% |
Dividend | - | P/FCF | - | EPS past 5Y | - | ROI | - | 52W High | -18.42% | Beta | - |
Dividend % | - | Quick Ratio | 41.60 | Sales past 5Y | - | Gross Margin | - | 52W Low | 102.28% | ATR | 3.14 |
Employees | 38 | Current Ratio | 41.60 | Sales Q/Q | - | Oper. Margin | - | RSI (14) | 58.82 | Volatility | 13.28% 12.06% |
Optionable | No | Debt/Eq | 0.00 | EPS Q/Q | - | Profit Margin | - | Rel Volume | 1.41 | Prev Close | 29.01 |
Shortable | Yes | LT Debt/Eq | 0.00 | Earnings | - | Payout | - | Avg Volume | 153.13K | Price | 31.01 |
Recom | 1.70 | SMA20 | 7.45% | SMA50 | 16.83% | SMA200 | 23.23% | Volume | 214,777 | Change | 6.89% |
![]() | ||||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||||
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune and neurodegenerative diseases. It focuses on the treatment of body, brain, and eye disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration. Its product candidates include ANX005, which has completed Phase 1b clinical trials to treat patients with guillain- barre syndrome; and ANX007, which has completed Phase 1b clinical trials to treat patients with glaucoma. The company's candidates also comprise ANX005 that has completed preclinical trials to treat patients with warm autoimmune hemolytic anemia, Huntington's disease, and amyotrophic lateral sclerosis; ANX007, which has completed preclinical trials for the treatment of geographic atrophy; and ANX009 that has completed preclinical trials for the treatment of systemic autoimmune diseases. The company was founded in 2011 and is headquartered in South San Francisco, California. | ||||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||||
![]() |
open in yahoo | open in reuters | open in google |
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite